论文部分内容阅读
目的观察缬沙坦治疗慢性心力衰竭的临床疗效。方法选择80例慢性充血性心力衰竭患者,心功能Ⅱ～Ⅳ级,随机分为治疗组和对照组各40例,对照组采用常规治疗方法,治疗组在常规治疗的基础上加用缬沙坦,治疗4个月,观察两组的临床疗效和心功能改变。结果治疗组治疗后LVEDD、LVESD、LVEF、左心室短轴缩短率(FS)及BNP较治疗前改善(P<0.05,P<0.01),对照组治疗后LVEDD、FS、LVEF较治疗前改善(P<0.05,P<0.01);两组治疗前比较,LVEDD、LVESD、FS、LVEF及BNP水平差异无统计学意义(P>0.05);两组治疗后比较,LVEDD、LVEF及BNP差异有统计学意义(P<0.05)。结论缬沙坦治疗慢性心力衰竭疗效好、不良反应少,患者耐受性佳,是慢性心力衰竭可靠的治疗药物。
Objective To observe the clinical efficacy of valsartan in the treatment of chronic heart failure. Methods Eighty patients with chronic congestive heart failure were enrolled in this study. The patients were divided into treatment group (n = 40) and control group (n = 40) randomly. Patients in the control group were treated with conventional therapy. The treatment group was given valsartan After 4 months of treatment, the clinical efficacy and cardiac function of the two groups were observed. Results After treatment, LVEDD, LVESD, LVEF, shortening of left ventricular shortening (FS) and BNP in treatment group were better than those before treatment (P <0.05, P <0.01) (P <0.05, P <0.01). There was no significant difference in LVEDD, LVESD, FS, LVEF and BNP between the two groups before treatment (P> 0.05). There was statistical difference between LVEDD, LVEF and BNP Significance (P <0.05). Conclusion Valsartan in the treatment of chronic heart failure with good efficacy, fewer adverse reactions, patients with good tolerance, reliable treatment of chronic heart failure drugs.